Business UpdateJul 1, 2026, 07:01 AM
Ocugen to Present OCU410 Phase 2 1-Year Results at Conferences
AI Summary
Ocugen, Inc. announced it will present on its innovative modifier gene therapy platform at several investor and industry conferences in July 2026. Key presentations include a fireside chat at Piper Sandler Virtual Ophthalmology Day and a panel discussion at the OIS Retina Innovation Summit. Most notably, the company will present OCU410 Phase 2 ArMaDa 1-year results and Phase 1/2 OCU410 quantitative FAF/SD-OCT analysis and safety outcomes at the American Society of Retina Specialists (ASRS) meeting.
Key Highlights
- Ocugen to present on its modifier gene therapy platform at investor and industry conferences in July 2026.
- Dr. Shankar Musunuri to participate in a fireside chat at Piper Sandler Virtual Ophthalmology Day on July 10, 2026.
- Company to join a panel discussion at OIS Retina Innovation Summit on July 14, 2026.
- OCU410 Phase 2 ArMaDa 1-year results to be presented at ASRS on July 17, 2026.
- Phase 1/2 OCU410 quantitative FAF/SD-OCT analysis and safety outcomes also to be presented at ASRS.
- A webcast of the Piper Sandler presentation will be available on Ocugen's investor website.
Price Impact
More from OCGN